GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » Cash Ratio

Radiopharm Theranostics (ASX:RAD) Cash Ratio : 0.15 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Radiopharm Theranostics's Cash Ratio for the quarter that ended in Dec. 2023 was 0.15.

Radiopharm Theranostics has a Cash Ratio of 0.15. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Radiopharm Theranostics's Cash Ratio or its related term are showing as below:

ASX:RAD' s Cash Ratio Range Over the Past 10 Years
Min: 0.15   Med: 1.75   Max: 5.23
Current: 0.15

During the past 2 years, Radiopharm Theranostics's highest Cash Ratio was 5.23. The lowest was 0.15. And the median was 1.75.

ASX:RAD's Cash Ratio is ranked worse than
91.72% of 1474 companies
in the Biotechnology industry
Industry Median: 3.03 vs ASX:RAD: 0.15

Radiopharm Theranostics Cash Ratio Historical Data

The historical data trend for Radiopharm Theranostics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Cash Ratio Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23
Cash Ratio
3.42 0.88

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio 5.23 3.42 1.75 0.88 0.15

Competitive Comparison of Radiopharm Theranostics's Cash Ratio

For the Biotechnology subindustry, Radiopharm Theranostics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Cash Ratio falls into.



Radiopharm Theranostics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Radiopharm Theranostics's Cash Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash Ratio (A: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=11.699/13.229
=0.88

Radiopharm Theranostics's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1.894/12.844
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Radiopharm Theranostics  (ASX:RAD) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Radiopharm Theranostics Cash Ratio Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics (ASX:RAD) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (ASX:RAD) Headlines

No Headlines